* Q4 sales of SEK 18m (ABGSCe 16m), EBIT -3.3m (ABGSCe -10m) * Momentum in SOFC coatings for data ce...
* Solid end to the year * AY'25/26e guidance seems fine * Fair value range of NOK 18-25 Solid end t...
CDON delivered a strong fourth quarter with accelerating momentum across key operational metrics.
* Strong international growth offset by the Nordics * Short-term Pricer headwind * Fair value range ...
Relais' Q4 was soft, with the top line and adjusted EBITA below LSEG Data & Analytics consensus.
Redeye cuts its base case to SEK10 (from SEK11) and bull case to SEK15 (from SEK17), trimming 2026 n...
Redeye retains its positive view of Carasent following the Q4 report.
* Softer Q4 numbers due to FX and tough comps * We raise EBITDA by 6% for '27e * Trading at 13-9x EV...
* Strong US performance more than offsets German weakness * EBIT up by 5-9% for '26e-'27e, driven by...
* Sweden and Norway improving, but Finland still weak * Estimates unchanged as somewhat better resul...
* Offering a business opportunity to system operators * Identifying the potential in closed-loop sys...
Redeye comments on Avensia’s preliminary sales figures for January 2026.
Nettoomsättningen i det fjärde kvartalet uppgick till 154,4 MSEK (119,8), motsvarande en tillväxt om...
Advenicas vd Marie Bengtsson gästar Västra Hamnens studio och diskuterar bolagets Q4-rapport, händel...
Redeye concludes that Litium delivered a strong Q4, with ARR growth of 18% including Geins and organ...
* We cut 2026e EBIT 4%, 2027e unchanged * Potential for large order signings near-term * Reiterate f...
* A soft end to '25 on earnings * We cut '26e-'27e adj.
Redeye comments on Active Biotech's fourth quarter report.
Redeye returns with an update on Sprint Bioscience following recent events and the Q4 report.
Vd Joakim Samuelsson diskuterar bokslutsrapporten, händelser under året, affärsmodellen, samt möjlig...